| Open Trial |
Description |
|
OV-16
Chemo
(Active)
Adjuvant 1st line Ovarian | |
Phase III study of Cisplatin + Topotecan x 4 PLUS Carbo + Taxol x 4 Versus Carbo + Taxol x 8 |
|
PFIZER
Targeted Therapy
(Hold)
Recurrent or persistent small volume ovarian |
Phase II study of CP547, 632, an oral tyrosine kinase inhibitor of VEGFR-2 |
| CINI |
|
RCT of Immediate Treatment as follow up for biopsy proven CINI | |
|
PHL019
Chemo + targeted therapy (Active) Ovarian & Recurrent Primary Peritoneal |
Phase II study of UCN01 + Topotecan in patients with advanced ovarian cancer |
|
PHL020
Avastin + Cyclo (Active) Recurrent Ovarian & Primary Peritoneal |
Phase II study of Bevacizumab + low dose oral Cyclophosphamide |
|
IND. 154
Five solid tumours including ovarian (Active) |
Phase I study of a clusterin antisense aligo-nucleatide (OGX-04) + low dose docetaxel |
|
IND. 155
Alkylphospolipids (Hold) Sarcoma including Uterine |
Phase II study of Perifosine (D-21266) PO daily |
| Recurrent Ovarian Cancer |
Treatment decision making in recurrent ovarian cancer |
| Recurrent Ovarian Cancer |
Bearing Witness |
|
EN5
Radiation (Active) Adjuvant Endometrium |
Phase III trial of pelvic rads versus observation post TAH/BSO-Stage 1 or 2A intermediate risk endometrial cancer |
|
IND.160
Targeted Therapy (Active) Recurrent Endometrium |
Phase II study of CC1-799 (Rapamycin) IV day 1, 8, 15, & 22 of 28 day cycles, a PTEN inhibitor |
|
PMH – PIE
Chemo (Active) Advanced Cervical |
Phase II study of Cisplatin, Irinotecan and Epirubicin in unresectable, locally advanced/metastatic cervical carcinoma |
|
GT – 1
Chemo (Active) Low Risk GTN |
Phase III study of Methotrexate versus Dactinomycin as primary management of low risk gestational trophoblastic neoplasm (GTN) |
